Carasent ASA (OM:CARA), a Norwegian cloud-based healthcare software provider, has reported a surprising profitability turnaround in its latest earnings release, challenging previous bearish market narratives. The Oslo-listed company’s Q2 results showed a 14% year-over-year revenue increase to NOK 98 million ($9.2 million) with EBITDA margins improving to 8%, reversing three consecutive quarters of declines.
Market analysts attribute the improvement to successful cost-cutting measures and growing adoption of Carasent’s Webdoc patient management platform in Scandinavia. “Their hospital SaaS solutions are gaining traction just as Nordic healthcare systems accelerate digital transformation,” noted a Stockholm-based tech sector analyst who requested anonymity due to employer restrictions.
However, some investors remain skeptical about the company’s ability to maintain momentum. Carasent’s stock remains 42% below its 2021 peak despite the recent 18% rally following the earnings announcement. The company faces intensifying competition from larger European health tech players like CompuGroup Medical and American rivals expanding into the region.
Looking ahead, much depends on whether Carasent can convert its Scandinavian foothold into broader European market penetration. Management guidance suggests planned expansions into Germany and Benelux markets could begin contributing to revenues by late 2024.